Ipilimumab (Yervoy®)

Assessment Status Assessment process complete
Drug Ipilimumab
Brand Yervoy®
Indication For the treatment of advanced (unresectable or metastatic) melanoma in adult patients who have received prior therapy.
Assessment Process
Rapid review commissioned 31/05/2011
Rapid review completed 09/06/2011
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.
Full pharmacoeconomic assessment commissioned by HSE 29/07/2011
NCPE assessment completed 02/09/2011
NCPE assessment outcome Reimbursement Not Recommended at the submitted price.

Technical Summary

September 2013

The HSE has approved reimbursement following confidential price negotiations.